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β2-Adrenergic receptor promoter haplotype
influences the severity of acute viral
respiratory tract infection during infancy: a
prospective cohort study
Pingsheng Wu1, Emma K Larkin1, Sara S Reiss1, Kecia N Carroll2, Marshall L Summar3, Patricia A Minton1,
Kimberly B Woodward1, Zhouwen Liu4, Jessica Y Islam5, Tina V Hartert1 and Paul E Moore6*

Abstract
Background: Despite the significant interest in β2-Adrenergic receptor (ADRB2) polymorphisms related to asthma,
whether ADRB2 genetic variants are similarly associated with acute respiratory tract infections have not been
studied. We hypothesized that genetic variants in ADRB2 associated with a response to asthma therapy during an
asthma exacerbation were also associated with severity of acute respiratory tract infections.
Methods: To test this hypothesis, we genotyped 5 common polymorphisms in the promoter region and coding
block of the ADRB2 gene (loci -2387, -2274, -1343, +46, and +79) from 374 Caucasian and African American term
infants who were enrolled at the time of acute respiratory illness over four respiratory viral seasons. Severity of
respiratory tract infections was measured using a bronchiolitis severity score (BSS; range = 0-12, clinically significant
difference = 0.5) with a higher score indicating more severe disease. We assigned the promoter, coding and
combined promoter and coding haplotypes to the unphased genotype data. The associations between each of
these five single-nucleotide polymorphisms (SNPs) as well as the haplotypes and infant BSS were analyzed using
nonparametric univariate analysis and multivariable proportional odds model separately in Caucasians and African
Americans.
Results: There was no significant association between infant BSS and each of the SNPs in both Caucasians and
African Americans. However, promoter haplotype CCA was associated with a decreased BSS in African Americans in
a dose dependent manner. The median (interquartile range) BSS of infants with no copies of the CCA haplotype,
one copy, and two copies of the CCA haplotype were 5.5 (2.0, 8.0), 4.0 (1.0, 7.5), and 3.0 (1.0, 4.0), respectively. This
dose dependent relationship persisted after adjusting for infant age, gender, daycare exposure, secondhand smoke
exposure, prior history of breastfeeding, siblings at home, and enrollment season (adjusted odds ratio: 0.59, 95 %
confidence interval: 0.36, 0.98). There was no similar protective relationship of haplotype CCA on severity of
respiratory tract infections identified in Caucasians.
Conclusions: ADRB2 genotype may be predictive of severity of acute respiratory tract infections in African
Americans, and potentially identify a subset of infants who may respond to beta-agonist therapy.
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Background
Respiratory tract infection is common in infants and
young children and is a major public health problem in
this age group [1]. It is mainly caused by infection of seasonal viruses, such as respiratory syncytial virus (RSV)
and rhinovirus [2–4]. Most infections manifest as an
upper respiratory infection, while 20–40 % develop lower
respiratory infection, and a small number (2 – 3 %) of infected infants require hospitalization [5, 6]. This is of particular concern as infants with lower respiratory viral
infection are at increased risk of developing recurrent
wheezing or childhood asthma [7–13]. Several risk factors
have been identified for the development of severe lower
respiratory viral infections, such as premature birth, young
age, being born in relation to the RSV season, underlying
chronic lung disease, congenital heart disease, high parity,
young maternal age and poor socioeconomic factors
[14–16]. Recently, genetic polymorphisms have been
identified which are associated with severe viral infection [17, 18]. Many of the identified genetic variants
associated with severe lower respiratory tract infections are also associated with and pathways common
to asthma, including innate immune genes involved
in cytokine and chemokine signaling, and epithelial
cell function [13, 17, 19–23].
As the clinical hallmark of asthma is wheezing, and
therapy includes beta agonists, a number of clinical studies over the past 2 decades have examined the relationship between genetic variants in β2-Adrenergic receptor
(ADRB2) and asthma [24–30]. The polymorphism that resulted in the Gly16 allele was associated with decreased
bronchodilator responses in early clinical studies; however,
larger clinical studies have provided equivocal results
[31–33]. Other genetic variants in the promoter region of ADRB2 have also been associated with asthma
severity [28, 34]. Despite the significant interest in
ADRB2 polymorphisms related to asthma, the relative
contribution of ADRB2 genetic variants to severity of
respiratory viral infections has not been established.
As wheezing is also the clinical hallmark of lower respiratory viral infections, and variable response to bronchodilators has been demonstrated in infants hospitalized with
RSV lower respiratory viral infections, it is possible that
ADRB2 genetic variants also contribute to the severity of
acute respiratory viral infections [35, 36].
The aim of the present study was to explore associations
between the genetic variants in ADRB2 that have been associated with a response to asthma therapy during an
acute asthma exacerbation and the severity of infant acute
respiratory viral infections. We examined the relationship
between 5 common polymorphisms in the promoter region and coding block of the ADRB2 gene and infant severity of respiratory infections in a prospective cohort of
Caucasian and African American infants.
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Methods
Study population

In order to examine the association of genetic variants in
the regulatory regions of the ADRB2 gene and the severity
of viral respiratory infections during infancy, we conducted an analysis of infants enrolled in the Tennessee
Children’s Respiratory Initiative (TCRI), a prospective cohort of mother-infant dyads enrolled during an infant’s
acute viral respiratory illness over four respiratory viral
seasons, 2004–2008. Term (≥37 weeks) and non-low birth
weight (≥2275 g) infants who were otherwise healthy with
no significant co-morbidities or cardio-pulmonary disease
were eligible, with oversampling for hospitalization infants. Eighty five percent of enrolled subjects had at least
one respiratory virus identified by polymerase chain reaction (RSV, rhinovirus, influenza, parainfluenza, Human
Metapneumovirus, and coronavirus); 56 % had labconfirmed RSV infection. The rationale, methods, and detailed inclusion and exclusion criteria have been reported
previously [37]. Although 630 infants were enrolled in
TCRI, this study was limited to the 261 Caucasian and
113 African American infants for whom DNA was available. The protocol was approved by the Institutional
Review Board of Vanderbilt University, and mothers provided informed consent for their infants. All parents provided written informed consent for both their and their
child’s study participation.
Infant acute respiratory infection severity

Infants included in this study had either upper respiratory tract infections or lower respiratory tract infections.
The severity of acute respiratory infection was determined by experienced research nurses through medical
record chart review using an ordinal bronchiolitis severity score (BSS). The score is an aggregate of assigned
values ranging of 0–3 in categories of respiratory rate,
room air oxygen saturation, the presence and extent of
wheezing, and the presence and extent of flaring and retractions [37–39]. The BSS ranges from 0 to 12, with
higher scores indicating more severe illness and a difference of 0.5 being a clinically significant difference [40].
We measured the BSS at the end of the outpatient visit
or after discharge from an inpatient admission, and the
most severe recorded value was used for analysis.
Genotype determination

DNA was extracted by Vanderbilt’s DNA core laboratory
from whole blood or saliva samples (Oragene by DNA
Genotek) by standardized protocols. All oragene samples
were processed immediately after collection, while blood
samples were either processed immediately or frozen before processing. Genotyping at five pre-specified loci
(-2387, -2274, -1343, +46, and +79) of ADRB2 gene was
done using Taqman SM© Genotyping Assays (Applied
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Biosystems, Foster City, CA, USA) with predetermined
primers. The five single-nucleotide polymorphisms (SNP)s
were rs1432623, rs11168068, and rs2400707 at the promoter region, and rs1042713 SNP and rs1042714 SNP at
the coding region of ADRB2 gene. Probes for the Applied
Biosystems assays used were labeled at their 5′end
with either VIC® or 6-carboxy-fluorescine (FAM) reporter dyes. The reaction components include: 2.5 μl
Taqman Universal PCR Master Mix (Applied Biosystems),
0.125 μl or 0.250 μl assay mix (Applied Biosystems) and
approximately 5 ng of genomic DNA in a total volume of
10 μl per single tube reaction. PCR amplification was performed in a thermal cycler (Techne TC-412) with an initial step of 95 °C for 10 min followed by 50 cycles of 92 °C
for 15 s and 60 °C for 1 min. After amplification, the fluorescence of each sample was read on the ABI 7900HT
(DNA Resources Core at Vanderbilt University) and analyzed with the Sequence Detection Software (Applied Biosystems). Five percent of samples were run as blind
duplicates with 100 % concordance. Primers and probes
for all SNPs are listed in Table 1.
Statistical analysis

The demographics and characteristics of the 374 infants
included, with either upper respiratory infection or lower
respiratory tract infection, are presented as frequencies
and proportions for specific categorical variables and
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medians and interquartile ranges were calculated for
continuous variables. All analyses were stratified by race
(Caucasian or African American), as a surrogate measure of European or African ancestry, to reduce the
known impact of population substructure which can
produce spurious associations [41]. A pairwise linkage
disequilibrium (LD) was estimated for the SNPs in
ADRB2 using the standardized summary statistics D’
and r, calculated by the HaploView program (Whitehead
Institute for Biomedical Research, Cambridge, MA, USA).
SNPs were tested for deviations from Hardy Weinberg
proportions, also using Haploview [42]. The promoter,
coding and combined promoter and coding SNPs were
assigned to blocks using D’ confidence interval of Gabriel
et al. [43]. Individual haplotypes were estimated using the
program PHASE v2.1.1 [44, 45]. The haplotype frequencies for each block were estimated using the expectation
maximization (EM) algorithm, again using the HaploView
program. Non-parametric Kruskal-Wallis test were applied to compare the difference in BSS among infants with
each SNP genotype, as well as each haplotype genotype.
Haplotype genotypes with frequency less than 2 % were
excluded from haplotype analysis. We used a proportional
odds model for the ordinal BSS to test the additive effect
of haplotypes. Covariates included in the regression model
included infant age at enrollment, gender, daycare exposure, secondhand smoke exposure, any prior history of

Table 1 Primers and probes of the 5 ADRB2 SNPs
Loci

rs number

Primers

Probes

−2387

rs1432623

Forward Primer

Vic- TCACACAAGTATAGTTTG

5′-TTCTAAACCACTAAGTAATTTATGTAAACTTCGCTT-3′
Reverse Primer

Fam- CACACAAGTGTAGTTTG

5′-GGTAAGCAAGAATTGAATGATATAGTAAGAAATATGAAAA-3′
−2274

rs11168068

Forward Primer

Vic- AATCACGAAGTACCTGATTT

5′-GGAAGTGACTTTATGCCCCTTTAGA-3′

Fam- TCACGAAGTACCTAATTT

Reverse Primer
5′-AGATTCACCAAACTTGGAGCTTTCT-3′
−1343

rs2400707

Forward Primer

Vic-TTCACATGGCACAACC

5′-TAAGTCACAG ACGCCAGATGGT-3′

Fam- CACATGGCGCAACC

Reverse Primer
5′-AACAAA CTATCCAGCA GATGAAAGGA T-3′
+16

rs1042713

Forward Primer

Vic- CAC CCAATGGAAGCC

5′- CGGCAGCGCCTTCTTGCTGGCAC-3′

Fam-CAC CCAATAGAAGCC

Reverse Primer
5′-TGCGTGACGTCGTGGTC-3′
+27

rs1042714

Forward Primer

Vic- TCGTCCCTTTGCTGCGT

5′-CCTTCTTGCTGGCACCCAAT-3′

Fam-TCGTCCCTTTCCTGCGT

Reverse Primer
5′-TGCCCACCACCCACAC-3′

Wu et al. BMC Medical Genetics (2015) 16:82

breastfeeding, any siblings at home, and enrollment season. All analyses were conducted separately according to
race. All analyses were performed using R-software version 2.11.1 (www.r-project.org). We used a two-sided 5 %
significance level for all statistical inferences.

Results
There were in total 374 infants, 261 Caucasians and 113
African Americans, enrolled in the TCRI cohort with
available DNA and at least one ADRB2 polymorphism
tested (Table 2). The median infants’ age at enrollment
was 11 weeks (interquartile range [IQR]: 6, 25). The average birth weight of these infants was 3317 g (standard deviation [SD]: 455.8). Among those infants, 207 (55 %)
were male, 198 (53 %) were breastfed, 107 (29 %) attended
daycare at the time of enrollment, 222 (60 %) were exposed to secondhand smoke, and 283 (76 %) had older
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siblings at home. Seventy six percent (n = 285) of infants
had bronchiolitis at enrollment and 64 % (n = 239) were
identified as RSV positive. The median bronchiolitis severity score was 5.5 (IQR: 2.5, 8.5). Compared to African
American infants, Caucasian infants were more likely to
have a higher birth weight, younger age at enrollment,
been breast fed, have secondhand smoke exposure, have
private insurance, have mothers who were older and had a
higher education level, and have mothers who were less
likely to have asthma. In addition, Caucasian infants were
more to have lower respiratory tract infection instead of
upper respiratory infection, and have more severe respiratory infections based on the BSS (p < 0.05).
Table 3 lists the allele frequencies of 5 SNPs separately
for Caucasian and African Americans. In both Caucasians
and African Americans, infants had slightly more T, T, and
G alleles for the three promoter SNP rs1432623,

Table 2 Characteristics of infants and their biological mothers (N = 374)
Caucasian (N = 261)

African American (N = 113)

P value

3345 (3090, 3657)

3147 (2892, 3430)

<0.001

Infant characteristics
Birth weight (grams) (N = 372), median (IQR*)
Gestational age (weeks) (N = 371), median (IQR)

39 (38,40)

39 (38,40)

0.498

Male gender, n (%)

140 (54)

67 (59)

0.313

Age at enrollment (weeks), median (IQR)

10 (6, 21)

18 (7, 35)

<0.001

Breastfeeding, n (%)

152 (58)

46 (41)

0.002

Daycare attendance, n (%)

68 (26)

39 (35)

0.096

Secondhand smoke exposure (N = 371), n (%)

158 (61)

64 (57)

0.486

Having siblings, n (%)

198 (76)

85 (75)

0.894

Private

111 (43)

9 (8)

<0.001

Medicare

135 (52)

101 (89)

None

15 (6)

3 (3)

2004 – 2005

42 (16)

21 (19)

2005 – 2006

76 (29)

38 (34)

2006 – 2007

75 (29)

31 (27)

2007 – 2008

68 (26)

23 (20)

RSV positive

180 (69)

59 (52)

0.002

Lower respiratory tract infection vs. upper respiratory infection, n (%)

213 (82)

72 (64)

<0.001

Bronchiolitis severity score (n = 373), median (IQR)

6.5 (3, 9)

4 (1, 7)

<0.001

27 (22, 31)

24 (21, 27)

<0.001

<12

42 (19)

16 (17)

0.004

12

56 (25)

41 (44)

Insurance type, n (%)

Season of enrollment, n (%)
0.590

Maternal characteristics
Maternal age at enrollment (years)
Maternal education, years (n = 313), n (%)

>12
Maternal asthma, n (%)
Abbreviations: IQR interquartile range

122 (55)

36 (39)

50 (19)

27 (24)

0.298
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rs11168068, and rs2400707, respectively. Additionally, the
distributions are similar among Caucasians and African
Americans. There was a significant difference between
Caucasians and African Americans in the frequency distribution of the two coding SNPs. In comparison with African Americans, Caucasians were more likely to have a G
allele of rs1042713 SNP, and less likely to have a C allele
of rs1042714 SNP.
Within each SNP, there was no statistical difference in
BSS among each genotype (Figs. 1 and 2). This non statistical difference was consistent within both Caucasians
and African Americans. Among African Americans, there
was a decreasing trend of the severity of acute respiratory
infection with an increasing number of copies of C, C,
and A allele of the three promoter SNPs rs1432623,
rs11168068, and rs2400707, respectively (Fig. 1). However,
analyses with additive models indicated no statistical significance (p > 0.05).
Among 25 (32) possible haplotype combinations, only
four haplotypes with more than 2 % of frequency were
identified (Table 4 and Fig. 3). There were two promoter
haplotypes and three coding block haplotypes. There were
no statistically significant differences in the promoter and
coding block haplotype frequencies between Caucasian
and African Americans. However, when all 5 SNPs were
combined, the distribution of haplotype frequency was
significantly different between Caucasians and African
Americans, with genotype CCAAC more common in African Americans and rare in Caucasians (p < 0.001).
Promoter haplotype CCA was associated with a decreased BSS in African Americans in a dose dependent
manner (p = 0.037 in the univariate analysis) (Fig. 4). Infants without the CCA haplotype had the highest BSS
(median 5.5, interquartile range [IQR]: 2.0, 8.0). Infants
with one copy of CCA haplotype had a lower bronchiolitis severity score (median 4.0, IQR: 1.0, 7.5). Infants
with 2 copies of the CCA haplotype had the comparatively lowest BSS (median 3.0, IQR: 1.0, 4.0). This dose
dependent relationship persisted after adjusting for infant age, gender, daycare exposure, secondhand smoke
exposure, prior history of breastfeeding, siblings at
home, and enrollment season (adjusted odds ratio: 0.59,

95 % confidence interval [CI]: 0.36, 0.98, p = 0.042). This
protective effect of CCA haplotype was consistent when
we categorized the acute respiratory infection into upper
respiratory infection and lower respiratory tract infection. In a similar dose dependent manner, infants with
more copies of CCA haplotype were less likely to have
lower respiratory tract infection compared with infants
with less copies of CCA haplotype (p = 0.05). On the other
hand, promoter haplotype TTG was associated with a
higher BSS in African Americans (Additional file 1).
The protective effect of CCA haplotype in African
Americans was identified in all combined haplotypes
with CCA combination (Figs. 5 and 6). However, due to
the sample size, the effect was not statistically significant. In addition, all African American infants with a
coding block haplotype GG had CCA combination in
their promoter region; therefore, there was a similar
additive protective effect of GG in African Americans
(Additional file 2). There was no relationship between
BSS and the other two coding block haplotypes in African
Americans (Additional files 3 and 4). This was also true
for the combined haplotypes (Additional files 5 and 6).
In both Caucasian and African American infants, there
were no significant relationships between BSS and coding block haplotypes except for GG haplotype among
African Americans (Additional file 2). This was also true
for the combined haplotypes. In general, there was no
significant relationship between BSS and any haplotypes
in Caucasian infants. There was no similar promoter
haplotype CCA relationship with BSS in Caucasians as
observed in the African Americans (Fig. 4).

Discussion
In this study we have identified a haplotype in the promoter region of the ADRB2 gene which is associated
with a decreased BSS in African American infants. This
promoter haplotype of the ADRB2 gene was not associated with the severity of respiratory infections in Caucasian infants. The common coding block polymorphisms,
corresponding to amino acid changes at codons 16 and
27, were not associated with a protective effect on severity of respiratory infections in Caucasian or African

Table 3 Allele frequencies of the 5 ADRB2 SNPs (P value compares the frequency difference between Caucasian and African
Americans)
P value

SNP

Caucasian
(N = 261)

African American
(N = 113)

N

Allele frequencies (%)

N

Allele frequencies (%)

rs1432623

C/T

252

42.9

57.1

111

44.6

55.4

0.785

rs11168068

C/T

252

42.5

57.5

110

45.0

55.0

0.679

rs2400707

A/G

260

42.3

57.7

111

44.1

55.9

0.832

rs1042713

A/G

233

36.9

63.1

104

50.0

50.0

0.033

rs1042714

C/G

244

57.2

42.8

106

78.8

21.2

<0.001
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Fig. 1 BSS distribution across each genotype of 3 promoter SNPs, stratified by race. The scatter plots of the distribution of BSS across genotypes
of 3 promoter SNPs (rs1432623, rs11168068, and rs2400707) separately for Caucasian and African American infants. We further overlay box-and-whisker
plot of BSS on each scatter plot. P values were obtained from non-parametric Kruskal-Wallis test

American infants. Our results agree with the studied
conducted by Janssen and colleagues, who found no relationship between the SNP rs1042713 and susceptibility
to RSV bronchiolitis in a European population [17].
This observation that the CCA promoter region haplotype is associated with a protective effect on respiratory
viral infection severity is similar to our observation in a cohort of adults hospitalized for an asthma exacerbation,
where this haplotype was associated with spirometric

improvement in response to asthma-specific therapy that
included beta-agonists and corticosteroids [34]. In that
study, we noted spirometric improvement only in Caucasian patients, although the small number of African American non-responders in that cohort may have limited our
ability to detect a similar effect in African Americans [34].
The mechanism by which a haplotype in the promoter
region of the ADRB2 gene is associated with a decreased
BSS is not known. However, we can speculate that

Wu et al. BMC Medical Genetics (2015) 16:82
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Fig. 2 BSS distribution across each genotype of 2 coding SNPs, stratified by race. The scatter plots of the distribution of BSS across genotypes of
2 coding SNPs (rs1042713 and rs1042714) separately for Caucasian and African American infants. We further overlay box-and-whisker plot of BSS
on each scatter plot. P values were obtained from non-parametric Kruskal-Wallis test

Wu et al. BMC Medical Genetics (2015) 16:82
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Table 4 Haplotype frequencies of the ADRB2 promoter and
coding block SNPs (Haplotype genotypes with less than 2 %
frequency were not shown in the table)
Caucasians

African Americans

(N = 261)

(N = 113)

P value

Promoter haplotype
CCA

42.77

44.86

TTG

56.20

53.74

0.636

Coding block haplotype
AC

37.40

50.47

GC

19.01

28.97

GG

43.18

20.56

0.622

Combined haplotype
CCAGG

41.32

20.56

TTGAC

35.33

25.70

TTGGC

19.63

28.04

CCAAC

1.24

23.83

<.001

ADRB2 promoter haplotype may alter ADRB2 expression on airway smooth muscle cells and thereby influence basal airway tone. McGraw et al. showed that SNPs
in the promoter region of the ADRB2 may regulate gene
expression [46]. Moore et al. demonstrated that ADRB2
genetic variants are associated with differences in
ADRB2 expression in cultured human airway smooth

muscle (HASM) cells, an in vitro system used as a model
for changes in the human airway [47] These studies were
performed prior to identification of the complex promoter haplotypes, and we are not aware that these haplotypes have been studied in HASM. Small differences in
airway tone could thus be important in the setting of
acute viral respiratory infections.
Although beyond the scope of the current observational study, we also speculate that ADRB2 genotype
might also influence response to bronchiolitis-specific
therapy. The primary goal of TCRI was to establish a
longitudinal, prospective investigation of infants and
their biological mothers on the acute and the long-term
health consequences of varying viral respiratory tract infections on early childhood outcomes [37]. Although a
BSS was assigned for each infant at acute care visit or
hospital admission, we did not study or quantify the effects of different treatments, including beta-agonist therapy. A number of clinical studies have suggested that
some infants with bronchiolitis appear to improve with
bronchodilator therapy, while on average it is not efficacious [48–50]. As ADRB2 is the primary target of bronchodilator therapy, variation in response to beta-agonists
might reflect genetic variants in ADRB2.
The diversity of SNPs of the ADRB2 gene was explored by Drysdale et al., using immortalized lymphocytes from 23 Caucasians, 19 African-Americans, 20
Asians, and 15 Hispanic-Latinos [27]. This report from

Fig. 3 Linkage disequilibrium (LD) plot in Caucasian (a) and African Americans (b). The plot illustrates the linkage disequilibrium mapping using
the HaploView program in Caucasian (a) and African Americans (b) at 5 loci of the B2-adrenergic receptor gene: -2633, -2274, -1343 (in the
promoter region), and +46 and +79 (in the coding block)

Wu et al. BMC Medical Genetics (2015) 16:82
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Fig. 4 BSS distribution stratified by copy number of promoter haplotype CCA and separated by race. The scatter plots and the box-and-whisker
plots of BSS across 0, 1, and 2 copies of promoter haplotype CCA for both Caucasian and African American infants. P values were obtained from
multivariable regression model adjusted for infant age at enrollment, gender, daycare exposure, secondhand smoke exposure, any prior history of
breastfeeding, any siblings at home, and enrollment season

Fig. 5 BSS distribution stratified by copy number of combined haplotype CCAGG and separated by race. The scatter plots and the box-and-whisker
plots of BSS across 0, 1, and 2 copies of combined haplotype CCAGG for both Caucasian and African American infants. P values were obtained from
multivariable regression model adjusted for infant age at enrollment, gender, daycare exposure, secondhand smoke exposure, any prior history of
breastfeeding, any siblings at home, and enrollment season

Wu et al. BMC Medical Genetics (2015) 16:82
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Fig. 6 BSS distribution stratified by copy number of combined haplotype CCAAC in African Americans infants. The scatter plots and the box-and-whisker
plots of BSS across 0, 1, and 2 copies of combined haplotype CCAAC for African American infants. P values were obtained from multivariable regression
model adjusted for infant age at enrollment, gender, daycare exposure, secondhand smoke exposure, any prior history of breastfeeding, any siblings at
home, and enrollment season

2000 included the 2 coding block SNPs (+46 and +79)
and a number of promoter SNPs extending to 1023 bp
upstream of the translation start site. Hawkins et al. examined a 5.3-kb region of the ADRB2 in 429 Caucasians
and 240 African-Americans and identified similar minor
allele frequencies in the 3 promoter SNPs (-2387, -2274,
and -1343) and in the coding block SNPs discussed in
this manuscript [28]. Such frequency distributions observed in our study are consistent with the allele frequencies reported in the reference population of the
International HapMap Project [51] and Hawkins et al.
[28]. Our stratified analyses by race therefore allow us to
detect the association between severity of a respiratory
illness and haplotype frequency within each racial group,
and to minimize the spurious associations due to such
population substructure.
We recognize that the significance of our findings is
limited by our small sample size and in classifying infants
in this study by a severity score rather than by measuring
some direct response to bronchodilator therapy. However,
BSS correlated with the severity of disease (classified as
upper respiratory and lower respiratory illness) well. Our
sensitivity analyses with the severity of disease (upper versus lower respiratory illness) showed consistent results indicated that BSS is a valid surrogate of disease severity.
Lastly, although a p value of 0.042 is at the threshold of
statistical significance, this p value reflects sample size of
113 African Americans in our study. Whether the

association between BSS and CCA haplotype in African
Americans is powerful or not depends upon not only p
value, but also upon the effect size such as odds ratio and
the clinical significance of the findings. As a difference of
0.5 in BSS is considered as clinically significant, a 65 % reduced odds of developing a more severe disease (higher
BSS) comparing 2 copies of CCA with 0 copy of CCA
might also be clinically significant and meaningful.
We hope that this hypothesis-generating study will encourage the incorporation of pharmacokinetic data in future studies of bronchiolitis. Although validation studies
in other populations are needed, this study underscores
that the development of personalized approaches to the
treatment of bronchiolitis may benefit from the analysis
of specific genetic variants.

Conclusions
In summary, we have observed that promoter region
haplotype of ADRB2 CCA is associated with a protective
effect on respiratory illness severity in African American
infants. In this era of personalized medicine, ADRB2
genotype may be predictive of the severity of respiratory
viral infection and potential response to therapy for the
most common acute infant illness and one for which we
currently have no therapy. Next steps would be to validate these findings, as well as evaluate available clinical
trial data for which DNA might be available.
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